Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 7, 2001, Pages 395-399

  Barker, Juliet N ^a   Martin, Paul L ^a   Coad, James E ^a   DeFor, Todd ^a   Trigg, Michael E ^a   Kurtzberg, Joanne ^a   Weisdorf, Daniel J ^a   Wagner, John E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Epstein Barr virus; Lymphoproliferative disorder; Unrelated donor umbilical cord blood transplantation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AZATHIOPRINE; BUSULFAN; CORTICOSTEROID; CYCLOSPORIN A; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MELPHALAN; METHYLPREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE DISEASE; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; AUTOPSY; BLOOD DONOR; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW DISEASE; BONE MARROW TRANSPLANTATION; CHILD; CONTROLLED STUDY; DEPLETION; DOSE RESPONSE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HLA MATCHING; HUMAN; HYPOTHESIS; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INBORN ERROR OF METABOLISM; INCIDENCE; LEUKEMIA; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; RECIPIENT; RISK FACTOR; T LYMPHOCYTE; UMBILICAL CORD BLOOD; UNIVERSITY HOSPITAL; WHOLE BODY RADIATION;

EID: 0034870232     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11529490     Document Type: Article

References (35)

1. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft-versus-host disease
2. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients
3. Outcome of cord-blood transplantation from related and unrelated donors
4. Outcomes among 562 recipients of placental-blood transplants from unrelated donors
5. First report of Epstein-Barr virus lymphoproliferative disease after cord blood transplantation
6. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia
7. High frequency of Epstein-Barr virus (EBV) lymphoblastoid cell line-reactive lymphocytes in cord blood: Evaluation of cytolytic activity and IL-2 production
8. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood
9. Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation
10. Haematopoietic cell transplantation in patients with fanconi anaemia using alternate donors: Results of a total body irradiation dose escalation trial
11. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop
12. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients
13. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
14. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders
15. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)
16. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hematopoietic stem-cell transplantation
17. Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load
18. Risk of Lymphoproliferative Disorders After Bone Marrow Transplantation: A Multi-Institutional Study
19. Epstein-Barr virus-associated B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome
20. Unrelated donor bone marrow transplantation (UBMT) in 5075 patients with malignant and non-malignant disorders: Impact of marrow T cell depletion (TCD)
21. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
22. Role of donor versus recipient type Epstein-Barr virus in post- transplant lymphoproliferative disorders
23. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation
24. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation
25. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation
26. Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses
27. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
28. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
29. Large ex vivo expansion of human umbilical cord blood CD4+ and CD8+ T cells
30. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
31. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
32. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
33. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
34. Treatment of post-transplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes